Table 2 Univariate and multivariate analyses of factors in predicting OS
From: Gab2 plays a carcinogenic role in ovarian cancer by regulating CrkII
Univariate | Multivariate | |||
|---|---|---|---|---|
HR (95% CI) | P Value | HR (95% CI) | P Value | |
Age | ||||
< 57 | Ref | |||
≥ 57 | 1.057(0.615–1.815) | 0.842 | ||
Menopause | ||||
NO | Ref | |||
Yes | 0.827(0.435–1.575) | 0.564 | ||
FIGO stage | ||||
I-II | Ref | Ref | ||
III-IV | 14.035(5.846–33.699) | < 0.001 | 3.267(1.127–9.518) | 0.029 |
Histological subtype | ||||
Serous | 2.425(0.875–6.726) | 0.089 | ||
Non-serous | Ref | |||
Grade | ||||
Low-grade | Ref | Ref | ||
High-grade | 1.223(1.054–1.917) | 0.038 | 2.469(0.913–5.999) | 0.012 |
Ascites | ||||
No | Ref | |||
Yes | 1.559(0.894–2.717) | 0.117 | ||
Treatment | ||||
PDS | Ref | |||
NACT + IDS | 1.476(0.810–2.691) | 0.203 | ||
Platinum resistance | ||||
NO | Ref | |||
Yes | 5.449((3.140–9.455) | < 0.001 | ||
Resistance | ||||
NO | Ref | |||
Yes | 0.713(0.348–1.462) | 0.356 | ||
lymph node metastasis | ||||
No | Ref | |||
Yes | 1.401(0.779–2.521) | 0.260 | ||
CrkII expression | ||||
Low | Ref | Ref | ||
High | 19.904(10.087–39.274) | < 0.001 | 15.763(6.913–35.943) | < 0.001 |
Gab2 expression | ||||
Low | Ref | Ref | ||
High | 10.320(5.730–18.589) | < 0.001 | 2.510(1.283–4.910) | 0.007 |